Due to their high target specificity and binding affinity, therapeutic antibodies are currently
the largest class of biotherapeutics. The traditional largely empirical antibody development …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

Therapeutic antibodies make up a rapidly growing segment of the biologics market.
However, rational design of antibodies is hindered by reliance on experimental methods for …

An individual's B cell receptor (BCR) repertoire encodes information about past immune
responses and potential for future disease protection. Deciphering the information stored in …

Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …

Antibodies are currently the most important class of biotherapeutics and are used to treat
numerous diseases. Recent advances in computational methods are ushering in a new era …

Conventional methods for humanizing animal-derived antibodies involve grafting their
complementarity-determining regions onto homologous human framework regions …

Despite recent advances in transgenic animal models and display technologies,
humanization of mouse sequences remains one of the main routes for therapeutic antibody …

Antibodies are versatile molecular binders with an established and growing role as
therapeutics. Computational approaches to developing and designing these molecules are …

Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small,
single-domain antibodies that are naturally expressed in camelids, are rapidly gaining …